Market News AIOpen the app

J.P. Morgan keeps its 'Buy' rating for Recursion Pharmaceuticals and sets a price target of $7.

OpinionRead the original at moomoo.com
Good for RXRX

J.P. Morgan reaffirmed its Buy rating and set a $7 target for Recursion.

RXRX · Recursion Pharmaceuticals, Inc.

AI read · Good for RXRX

The AI's read

That gives investors a favorable outside view of Recursion's shares. The report offers no new facts about its research, sales, or cash, so the support rests on the analyst's opinion alone.

Get alerts for RXRX

Follow Recursion Pharmaceuticals, Inc. (RXRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RXRX
Free on the App Store and Google Play, or on the web.